IngredientsAmerican Liverleaf — known formally as Anemone hepatica (synonym Hepatica nobilis) — is a species of flowering plant in the buttercup family Ranunculaceae, native to woodland in temperate regions of the Northern Hemisphere. Within the North American context, the primary species carrying the common name "American Liverleaf" is the round-lobed form. In the Botanical Register (1819), Ker figured the round-lobed form, considered it a distinct species, and named it Hepatica americana; De Candolle followed him in his Prodromus (1824).
The taxonomy of this genus has long been disputed and remains unsettled. Some botanists lump the round-lobed hepatica (Hepatica americana) with the sharp-lobed hepatica (Hepatica acutiloba) as separate varieties of a single species, H. nobilis; round-lobed hepatica is then designated H. nobilis var. obtusa. Other botanists include the plants in the genus Anemone, making them round-lobed hepatica: A. americana, and sharp-lobed hepatica: A. acutiloba.
Parts used medicinally include the dried plant of Anemone acutiloba Lawson, and Anemone Hepatica Linn., Natural Order Ranunculaceae, Tribe Anemoneae.
Common names include Liverleaf, Liverwort, Noble Liverwort, American Liverleaf, Kidney Liverleaf (A. Hepatica), Heart Liverleaf (A. acutiloba), and Hepatica. "Liverleaf" and "Liverwort" both reference its liver-shaped leaves, while "Kidneywort" likely arose from the kidney-like appearance of its seeds.
The botanical name Hepatica is believed to have originated from the Greek word hepar, meaning "liver," as well as the Latin word epatikos, meaning "affecting the liver." The common name "liverleaf" refers to the supposed liver-like leaf shape, and perhaps also to the liver-like color of the overwintering brown leaves.
This herbaceous perennial grows from a rhizome and reaches 5–15 cm high. Leaves and flowers emerge directly from the rhizome, not from a stem above ground. The leaves have three lobes and are fleshy and hairless, 7–9 cm wide and 5–6 cm long. The upper side is dark green with whitish stripes and the lower side is violet or reddish brown. Leaves emerge during or after flowering and remain green through winter.
The flowers are blue, purple, pink, or white and appear in winter or spring. They have five to ten oval showy sepals and three green bracts. Hepatica is a native North American species found in woodlands throughout the eastern United States and parts of southeastern Canada. The closely related sharplobe hepatica (H. nobilis var. acuta) is native to the Northeast and Southeast and is found in most states east of the Mississippi River, extending from Ontario, Quebec, and Maine south through the eastern United States to Missouri, Georgia, and Alabama.
It is primarily the leaves that have been used in herbal medicine. The leaves are collected from late spring to mid-summer and dried for later use in liquid extracts and tinctures. The entire plant is sometimes employed; it occurs in market in broken masses of leaves, sometimes intermixed with broken roots, and of a green color. It is odorless and has a subastringent and viscid taste, and yields its virtues to water.
A wide variety of liverleaf products — from bulk, dried leaves to capsules and tinctures — are available year-round in most specialty health food stores and through online retailers. Liverleaf capsules are available as an antioxidant liver support for humans and pets alike; the herb is often mixed with other herbs, such as milk thistle.
The name "liverwort," sometimes erroneously applied to liverleaf, properly belongs to the cryptogam Marchantia polymorpha and others of the same family. The two plants are entirely unrelated. The demand for and interest in liverwort (Marchantia polymorpha L.), an entirely different plant from hepatica, soared in the 1880s, likely due to mistaken identity and an attempt to fill the demand for the popular cure-all hepatica. This demand became known as the "hepatica boom."
Medieval herbalists believed hepatica could be used to treat liver diseases, and it may be used in current folk medicine. At that time, herbalists both in America and in Europe deemed the plant useful for treating liver ailments. This belief was based on the ancient "Doctrine of Signatures," a system in which the morphology of the plant — whether shape, color, or growth form — signified what illnesses the plant might be used to treat.
J. Bauhin stated that the herb was chiefly used by surgeons living around the middle of the 16th century for healing wounds, being used both externally and internally; also in decoction as a gargle in inflamed throat. Nicholas Culpeper, the 17th-century English herbalist, recommended liverwort for treating "bites of mad-dogs."
During the Medieval period, hepatica gained prominence in Europe for its medicinal properties. It was often used to treat ailments related to the liver and digestive system.
Native American tribes, including the Iroquois, valued hepatica for its medicinal properties. They used the leaves to brew teas believed to treat liver disorders, digestive issues, and skin ailments. European settlers adopted similar practices, incorporating hepatica into their own herbal remedies.
The early immigrants to North America valued the herb as a remedy for hepatitis and found that the natives used a closely related species, sharp-lobed hepatica (H. acutiloba), similarly. American Liverleaf (Hepatica americana) has a history of traditional use by Native Americans and early European settlers in North America, primarily as a remedy for liver disorders and as a general tonic.
Hepatica was introduced in the Philadelphia edition of the second issue of the U.S. Pharmacopoeia (1830), but was omitted from the New York edition of the same date. It occupied a position in the secondary department of each revision from 1830 to 1880, at which latter date it was discarded.
The liver-leaf held a place among medicinal plants from ancient times until falling into disuse in the last part of the 1800s when it was dismissed from the U.S. Pharmacopoeia. The plant held mild properties, forming a slightly astringent, mucilaginous infusion. It was used to treat coughs and other lung affections, as well as diseases of the liver.
Undoubtedly, the demand for the cryptogamic liverwort led to the "hepatica boom" about the year 1880. In 1883, the consumption of liverleaf in this country alone was about 450,000 pounds.
The herb was widely used in folk medicine, particularly for the treatment of diseases of the liver and gallbladder. The early immigrants to North America found that the natives used a closely related species similarly. In earlier times it was a widespread practice to eat the first emerging flowers in the spring, as they were said to protect against viper bites and a number of diseases in the coming year.
Eclectic physicians characterized hepatica as a "mild mucilaginous astringent." It was used in infusion, and is odorless, with a subastringent and viscid taste, yielding its virtues to water. Preparations included hot and cold infusions (teas), decoctions, liquid extracts, tinctures, poultices, gargles, and ointments. Extracts or decoctions made from the leaves were used in herbal medicine for the treatment of liver ailments, gallbladder ailments, and digestive disorders. The herb was once used to treat slow-healing wounds, minor injuries, ringworm, sunburn, and to get rid of freckles. In homeopathy, it is still used in diluted alcohol extract against bronchitis.
The main ingredients found in hepatica are mucous substances, tannins, sugars, flavonoids, anthocyanins, and saponin glycosides. The plant also harbors tannins, which provide astringent properties, along with mucilage, gums, sugars, chlorophyll, and minor amounts of bland oleoresin. Flavonoids and phenols have been detected in phytochemical screenings, though in modest concentrations without prominent bioactive potency.
Rafinesque's 1828 analysis — the earliest documented examination of the plant's chemistry — described it as "scentless and nearly insipid, not bitter; but a little astringent and mucilaginous. It contains tannin, mucilage, extractive, etc." A later 19th-century analysis by Harter, published in the Pharmaceutical Record (1884), corroborated this characterization: it contains none of the classes of active constituents found in medicinal plants, but consists of the usual constituents of plants, such as tannin, gum, and sugar.
Unlike some congeners in the Anemone genus, A. hepatica lacks high levels of triterpenoid saponins, alkaloids, or steroids that confer notable pharmacological effects in other species.
It is thought that most of the health benefits of hepatica come from its high content in mucilage, tannins, and flavonoids. Mucilage forms a protective layer over inflamed mucous membranes of the throat and mouth, counteracting the urge to cough. Flavonoids show antispasmodic and antioxidant activity, preventing damage caused by free radicals.
Protoanemonin's ability to inhibit both gram-positive and gram-negative bacteria is linked to the presence of a 5-membered lactone ring with a highly reactive double bond system. This bactericidal property, however, disappears upon drying, as the compound converts to the less active anemonin.
No dedicated mechanistic pharmacological studies specifically on Hepatica americana constituents have been identified in the peer-reviewed literature. The mechanisms attributed above are largely inferred from the known pharmacology of the individual compound classes (flavonoids, tannins, mucilage) as studied across multiple plant species, not from direct clinical or animal research on hepatica preparations.
Hepatica has customarily been used for liver issues as well as coughs, lung ailments, indigestion, constipation, and hemorrhoids. However, little scientific research has been undertaken to prove these traditional uses. Although hepatica has been used for centuries to treat a variety of health conditions, science has yet to uncover the exact mechanisms behind its medicinal actions.
Herbalists both in America and in Europe deemed the plant useful for treating liver ailments. This belief was based on the ancient "Doctrine of Signatures," a system in which the morphology of the plant signified what illnesses the plant might be used to treat. The signature theory wrongly links the shape of its leaves with liver benefits that have not been scientifically proven.
No clinical trials, controlled human studies, or robust in-vivo animal studies specifically examining hepatica's hepatoprotective or choleretic effects have been identified. The claimed liver benefits of hepatica are currently supported only by historical and ethnobotanical records.
Hepatica has been used to treat fevers, coughs and colds, and bleeding from the lungs. The plant's mucilaginous and astringent properties make it a proposed herb for treating bronchitis. The proposed mechanism — mucilage forming a protective coating over inflamed airway membranes — is plausible based on the known behavior of mucilaginous substances generally, but no clinical studies on hepatica preparations for respiratory conditions have been identified in the peer-reviewed literature.
Some ethnobotanical sources mention hepatica's use for external applications, such as poultices, to support wound healing including minor burns and scalds. These traditional uses were largely based on the plant's astringent properties, which were thought to help in drying and protecting wounds and soothing inflamed skin. There is virtually no scientific evidence supporting the efficacy of American Liverleaf for treating burns or scalds. Modern pharmacological studies are lacking, and no clinical trials have evaluated its effects on burn healing, pain relief, or infection prevention. The evidence for this use comes almost exclusively from anecdotal reports and historical herbal texts, not from controlled scientific investigation.
Protoanemonin's ability to inhibit both gram-positive and gram-negative bacteria is linked to the presence of a 5-membered lactone ring with a highly reactive double bond system. Tannins present in hepatica are water-soluble polyphenols that have been shown to protect the body from oxidative damage. These antioxidant compounds have also shown antimicrobial properties, effectively inhibiting the growth of many fungi, yeasts, bacteria, and viruses. These observations, however, are based on the general chemistry of the compound classes — direct antimicrobial assays of hepatica extracts in peer-reviewed literature have not been identified.
Hepatica extract has long been used to treat gallstones, and its mildly astringent properties can help calm an upset stomach and stimulate contractions in the intestines to help promote proper bowel function. This application remains grounded in traditional use and the known properties of astringent/tannin-rich preparations. No clinical studies specifically evaluating hepatica for gastrointestinal outcomes have been identified.
The presence of flavonoids, anthocyanins, and tannins in hepatica confers theoretical antioxidant activity on the basis of well-established phytochemistry. Tannins are water-soluble polyphenols present in many plants which have been shown to protect the body from oxidative damage. No dedicated in-vitro or clinical antioxidant studies on hepatica extracts specifically have been identified in peer-reviewed sources available for this review.
The totality of evidence for all proposed therapeutic uses of American Liverleaf is very weak by contemporary standards. Its use has been displaced today by caution regarding its toxicity and the lack of solid clinical evidence regarding its supposed liver benefits. There are no published randomized controlled trials, no systematic reviews, and no regulatory agency monographs (e.g., EMA, WHO, or German Commission E) specifically covering Hepatica americana as a medicinal substance. All claimed pharmacological activities remain at the level of traditional use, theoretical extrapolation from constituent chemistry, or very preliminary in-vitro data.
Eclectic physicians classified hepatica as a mild mucilaginous astringent. The following dosage information is drawn from historical herbal texts and must be understood in that context, as no modern clinical trials have established evidence-based dosage recommendations.
The plant held mild properties, forming a slightly astringent, mucilaginous infusion. It was used to treat coughs and other lung affections, as well as diseases of the liver. As a pectoral, it was noted that it "may be taken in the form of an infusion, hot or cold, in almost any amount, as its virtues are not of a powerful or disturbing nature" (Millspaugh, American Medicinal Plants, 1882).
It is primarily the leaves that have been used in herbal medicine. The leaves are collected from late spring to mid-summer and dried for later use in liquid extracts and tinctures.
A wide variety of liverleaf products — from bulk, dried leaves to capsules and tinctures — are available year-round in most specialty health food stores. Contemporary preparations also include diluted alcohol extract used in homeopathy against bronchitis. No specific mg-per-day dosages for hepatica preparations appear in peer-reviewed clinical research, and quantitative dosing guidance is absent from modern regulatory monographs.
Like other species in the buttercup family, hepatica contains the toxic substance protoanemonin. When the plant is wounded or macerated, ranunculin is enzymatically broken down into glucose and protoanemonin.
The plant should never be used fresh or in high doses due to the presence of protoanemonin, which can be dangerous and cause serious side effects such as vomiting, diarrhea, abdominal pain, mucous membrane irritation, and even skin blisters. The dried plant should always be used to minimize risks.
Avoid fresh leaves as they contain the toxic substance protoanemonin, which is converted to anemonin when dried. Hepatica is poisonous in large doses.
Very little protoanemonin appears to be provided by Caltha palustris L. (marsh marigold) and Hepatica nobilis Schreb. (liverleaf), placing them among the lower-risk members of the Ranunculaceae. This is consistent with the historical observation that hepatica contains smaller amounts of protoanemonin than other plants of the buttercup family.
Protoanemonin has vesicant properties, which cause rashes or blistering upon contact with the skin or mucosa. Ingesting large amounts of the toxin can cause nausea, vomiting, dizziness, spasms, acute hepatitis, jaundice, or paralysis in animals and humans.
Ingestion of larger quantities of the fresh plant results in severe irritation of the mucous membranes of the mouth, throat, and bronchi, gastroenteritis with nausea, vomiting, and diarrhea, which may be bloody, and — due to excretion of protoanemonin by the kidneys — nephritis. After absorption, excitatory and later paralytic states can occur. Hepatitis (jaundice) is possible. Lethal doses cause death by respiratory paralysis 1–2 days after ingestion.
The sap of plants of the family Ranunculaceae has a burning taste and may cause reddening of the skin followed by swelling and even blistering. If swallowed in large quantities, stomach irritation may follow and further develop into stomach colic and extreme gastroenteritis and diarrhea mixed with blood. Handling crushed leaves can cause skin irritation or blistering for some people. It is toxic to pets and humans if ingested in large quantities, leading to mouth irritation and digestive upset.
Prolonged or excessive use may cause kidney and urinary tract irritation, digestive discomfort, vomiting, diarrhea, and stomach pain. This is pharmacologically consistent with the known renal excretion pathway of protoanemonin and its irritant properties.
Its use is not recommended during pregnancy and lactation, except under the supervision of a qualified professional. No controlled safety data in pregnant or lactating humans or animals were identified in the reviewed sources.
As hepatica is now an endangered species in some regions, those who cultivate this herb should be supported instead of harvesting it from the wild. It is not often used in modern herbalism and is an endangered species.
No published pharmacokinetic drug-interaction studies involving hepatica extracts or its isolated constituents have been identified. The known chemical profile — modest levels of tannins, flavonoids, and mucilage — does not currently suggest major interaction signals with pharmaceutical drugs, but this reflects an absence of research rather than confirmed safety.
Hepatica occupied a position in the secondary department of the U.S. Pharmacopoeia from 1830 to 1880, at which date it was discarded. It is not currently monographed by the European Medicines Agency (EMA), the German Commission E, or the WHO as an approved herbal medicinal product. Its status as a dietary supplement ingredient in the United States means it is not subject to pre-market efficacy review by the FDA.
Health conditions that American liverleaf may help support.
Body systems that American liverleaf may help support.
Go back